Suppr超能文献

在 MPL/明矾佐剂中灭活的 HSV-2 可提供近乎完全的保护,防止长期挑战和再挑战后生殖器感染和脱落。

Inactivated HSV-2 in MPL/alum adjuvant provides nearly complete protection against genital infection and shedding following long term challenge and rechallenge.

机构信息

Department of Cellular and Molecular Medicine University of California, San Diego, La Jolla, CA 92093-0712.

Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093-0712.

出版信息

Vaccine. 2012 Oct 12;30(46):6541-6550. doi: 10.1016/j.vaccine.2012.08.049. Epub 2012 Sep 1.

Abstract

Herpes Simplex Virus Type 2 (HSV-2) infection can result in life-long recurrent genital disease, asymptomatic virus shedding, and transmission. No vaccine to date has shown significant protection clinically. Here, we used a mouse model of genital HSV-2 infection to test the efficacy of a vaccine consisting of whole, formalin-inactivated HSV-2 (FI-HSV2) formulated with monophosphoryl lipid A (MPL) and alum adjuvants. Vaccine components were administered alone or as a prime-boost immunization together with DNA vaccines encoding a truncated glycoprotein D2 (gD2t) and two conserved HSV-2 genes necessary for virus replication, UL5 (DNA helicase) and UL30 (DNA polymerase). Our results show: (1) compared with mock immunized controls, mice immunized with FI-HSV2 plus MPL/alum consistently showed protection against disease burden and total viral shedding while the mice immunized with gD2t protein with MPL/alum did not; (2) protection against genital disease and viral replication correlated with the type of boost in a prime-boost immunization with little advantage afforded by a DNA prime; (3) intramuscular (i.m.) immunization with FI-HSV2 in MPL/Alhydrogel adjuvant provided nearly complete protection against vaginal HSV-2 shedding after a lethal intravaginal (i.vag.) short-term challenge and long-term rechallenge; (4) single formulation immunization with DNA vaccines, FI-HSV2, and MPL in an aluminum phosphate (Adju-Phos) adjuvant did not increase protection relative to FI-HSV2/MPL/Adju-Phos alone; and (5) addition of MPL/alum to the FI-HSV2 was required for optimal protection against disease, viral replication, and latent virus load in the dorsal root ganglia (DRG). Most notably, an optimized vaccine formulation of FI-HSV2 MPL/Alhydrogel given i.m. completely protected against detectable vaginal HSV-2 shedding in the majority of animals and HSV-2 latent DNA in the DRG of all animals.

摘要

单纯疱疹病毒 2 型(HSV-2)感染可导致终身复发性生殖器疾病、无症状病毒脱落和传播。迄今为止,尚无疫苗在临床上显示出显著的保护作用。在这里,我们使用生殖器单纯疱疹病毒 2 型(HSV-2)感染的小鼠模型来测试由全细胞、福尔马林灭活单纯疱疹病毒 2 型(FI-HSV2)与单磷酰脂质 A(MPL)和铝佐剂组成的疫苗的功效。疫苗成分单独使用或作为与编码截短糖蛋白 D2(gD2t)和两种用于病毒复制的单纯疱疹 2 型保守基因 UL5(DNA 解旋酶)和 UL30(DNA 聚合酶)的 DNA 疫苗的初免-加强免疫一起使用。我们的结果表明:(1)与模拟免疫对照相比,用 FI-HSV2 加 MPL/ 铝佐剂免疫的小鼠始终表现出对疾病负担和总病毒脱落的保护作用,而用 MPL/ 铝佐剂免疫 gD2t 蛋白的小鼠则没有;(2)对生殖器疾病和病毒复制的保护作用与初免-加强免疫中的增强类型相关,DNA 初免几乎没有优势;(3)在 MPL/Alhydrogel 佐剂中肌肉内(i.m.)免疫 FI-HSV2 在致命的阴道内(i.vag.)短期挑战和长期再挑战后几乎完全防止阴道单纯疱疹 2 型脱落;(4)用 DNA 疫苗、FI-HSV2 和铝磷酸(Adju-Phos)佐剂的单一配方免疫不会增加相对于单独使用 FI-HSV2/MPL/Adju-Phos 的保护作用;(5)FI-HSV2 中添加 MPL/ 铝佐剂是预防疾病、病毒复制和背根神经节(DRG)潜伏病毒载量的最佳保护所必需的。值得注意的是,肌肉内给予优化的 FI-HSV2 MPL/Alhydrogel 疫苗配方完全保护大多数动物的阴道单纯疱疹 2 型脱落和所有动物的 DRG 中单纯疱疹 2 型潜伏 DNA 免受检测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be28/3754855/9c67ee99909e/nihms-404016-f0001.jpg

相似文献

引用本文的文献

3
Vaccines to prevent genital herpes.预防生殖器疱疹的疫苗。
Transl Res. 2020 Jun;220:138-152. doi: 10.1016/j.trsl.2020.03.004. Epub 2020 Mar 16.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验